Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 1:14:1394057.
doi: 10.3389/fonc.2024.1394057. eCollection 2024.

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Bei Hu  1 , Victoria Korsos  2 , M Lia Palomba  2   3
Affiliations
Review

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Bei Hu et al. Front Oncol. .

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.

Keywords: chimeric antigen receptor T cell therapy (CAR T cell therapy); diffuse large B cell lymphoma (DLBCL); high grade B cell lymphoma; mantle cell lymphoma (MCL); relapsed and refractory lymphoma.

PubMed Disclaimer

Conflict of interest statement

BH participated on advisory board for Janssen Biotech and Pharmacyclics. Research funding to institution from BMS, Genentech/Roche, and Beigene. MP has received research funding and honorarium from BMS, Cellectar, Ceramedix, Juno, Kite MustangBio, Garuda Therapeutics, Novartis, Pluto Immunotherapeutics, Rheos, Seres Therapeutics, Smart Immune, Thymofox, Synthekine. Received other from June and Seres. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. (2017) 130:1800–8. doi: 10.1182/blood-2017-03-769620 - DOI - PMC - PubMed
    1. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. . Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. (2015) 26:1175–9. doi: 10.1093/annonc/mdv111 - DOI - PubMed
    1. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. . Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Hematol Oncol. (2017) 35:528–35. doi: 10.1002/hon.2380 - DOI - PubMed
    1. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. . Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. (2018) 183:578–87. doi: 10.1111/bjh.15567 - DOI - PubMed
    1. Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. . Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. (2016) 127:1559–63. doi: 10.1182/blood-2015-10-673145 - DOI - PubMed

LinkOut - more resources